Sarepta Therapeutics (SRPT) PT Raised to $185 at Janney
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- Tech stocks power S&P 500 to record high as oil, producer inflation weaken
- Oil falls more than 3% on weaker global demand outlook and US crude buildup
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
3 Reasons the Sarepta Therapeutics (SRPT) Deal Looks Favorable - Citi
December 26, 2019 6:28 AM ESTCiti analyst, Joel Beatty, reiterated a Buy rating and $177.00 price target on Sarepta Therapeutics (NASDAQ: SRPT) after the company announced a deal that would provide an upfront $1.15B upfront payment, ongoing royalty payments and development cost sharing in exchange for non-U.S. product rights.
The analyst believes this benefits... More
